-
Technology Platforms
One of our key assets is our proven PEGylation technology. As a scientist, it is exciting to be associated with a technology that has brought hope to so many patients with serious diseases like cancer.
Technology Platforms
We continue to apply our PEGylation technology to a broad range of therapies, such as the PEGylated version of SN38, which has shown very encouraging results in preclinical studies.” — Hong Zhao Ph.D., Director, Organic and Medicinal Chemistry. Enzon is dedicated to developing innovative therapies through a variety of advanced technologies. Enzon’s proprietary PEGylation technology is a proven means of enabling or enhancing the performance of pharmaceuticals with delivery limitations, through the chemical attachment of polyethylene glycol or PEG via a linker. Advantages of PEGylation include increased efficacy, reduced toxicity, increased stability, and enhanced solubility. Click here to learn more about Enzon’s PEGylation technologies. Enzon has also developed Customized Linker Technology™, which utilizes linkers designed to release the native molecule at a controlled rate. Enzon is also developing eight innovative RNA antagonists based on the Locked Nucleic Acid® (LNA) Technology. Click here to learn more about this technology.
Search
Enter your email address to sign up for the Enzon mailing list.
News
-
08-03-2010
Enzon Reports 2nd Quarter 2010...
Enzon Reports 2nd Quarter 2010 Results
-
07-27-2010
Enzon to Release Second Quarte...
Enzon to Release Second Quarter 2010 Earnings on Tuesday, August 3, 2010; Conference Call and Webcast to Follow
-
05-10-2010
Enzon Reports 1st Quarter 201...
Enzon Reports 1st Quarter 2010 Results
-
05-07-2010
Enzon Sets Date of 2010 Annual...
Enzon Sets Date of 2010 Annual Meeting
-
07-27-2009
Enzon to Release Second Quarte...
Enzon to Release Second Quarter 2009 Earnings on Tuesday, August 4, 2009; Conference Call and Webcast to Follow
-
02-13-2009
Enzon to Release Fourth Quarte...
Enzon to Release Fourth Quarter 2008 Earnings on Thursday, February 19, 2009; Conference Call and Webcast to Follow
-
10-29-2008
Enzon to Release Third Quarter...
Enzon to Release Third Quarter 2008 Earnings on Wednesday, November 5, 2008; Conference Call and Webcast to Follow
-
10-20-2008
Enzon Presents New Data on its...
Enzon Presents New Data on its LNA Programs
--Platform shows promise--
-
12-03-2009
Enzon Board Authorizes Share R...
Enzon Board Authorizes Share Repurchase of up to $50 Million
-
02-10-2009
Enzon Announces IND Acceptance...
Enzon Announces IND Acceptance for its Survivin Antagonist
-- Phase I study to open for patients with solid tumors-- -
10-30-2007
Enzon Reports Third Quarter 20...
Enzon Reports Third Quarter 2007 Results
-
07-29-2008
Enzon to Release Second Quarte...
Enzon to Release Second Quarter 2008 Earnings on Wednesday, August 6, 2008; Conference Call and Webcast to Follow